Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation
Authors:
- Hong-Bo XiaoHXHong-Bo Xiao
- Zhi-Liang SunZSZhi-Liang Sun
- Heng-Bo ZhangHZHeng-Bo Zhang
- Da-Sheng ZhangDZDa-Sheng Zhang
- 1 July 2012
- journal article
- Published by Springer Nature in Pharmacological Reports
- Vol. 64 (4) , 889-895
Abstract
Inhibiting the action of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the low-density lipoprotein receptor (LDLR) has emerged as a novel therapeutic target for hypercholesterolemia. Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation. Forty female mice were divided into four groups (n =10): control, LPS (5 mg/kg), LPS + berberine 10 (5 mg/kg LPS plus 10 mg/kg berberine), and LPS + berberine 30 (5 mg/kg LPS plus 30 mg/kg berberine). Changes in the levels of blood lipids [total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C)]; pro-inflammatory cytokines [interferon-γ (IFNγ), tumor necrosis factor α (TNFα), and interleukin-1α (IL-1α)], 8-isoprostane, hepatic expressions of PCSK9 and LDLR were determined. Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNγ, TNFα, IL-1α, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice. The present results suggest that berberine inhibits dyslipidemia in C57BL/6 mice with LPS induced inflammation through regulating PCSK9-LDLR pathway.Keywords
This publication has 31 references indexed in Scilit:
- Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammationPharmacological Reports, 2011
- Antioxidant Properties and Associated Mechanisms of SalicylatesCurrent Medicinal Chemistry, 2011
- PCSK9: an emerging target for treatment of hypercholesterolemiaExpert Opinion on Therapeutic Targets, 2010
- Physicochemical Characterization of Berberine Chloride: A Perspective in the Development of a Solution Dosage Form for Oral DeliveryAAPS PharmSciTech, 2010
- Cardiovascular and metabolic effects of BerberineWorld Journal of Cardiology, 2010
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial HypobetalipoproteinemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery DiseaseEndocrine, Metabolic & Immune Disorders - Drug Targets, 2008
- Berberine decreases PCSK9 expression in HepG2 cellsAtherosclerosis, 2008
- Statins Upregulate PCSK9 , the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003